Mazin Sabra - Clearpoint Neuro Chief Officer
| CLPT Stock | USD 17.61 0.18 1.01% |
Insider
Mazin Sabra is Chief Officer of Clearpoint Neuro
| Age | 44 |
| Address | 120 S. Sierra Avenue, Solana Beach, CA, United States, 92075 |
| Phone | 888 287 9109 |
| Web | https://www.clearpointneuro.com |
Mazin Sabra Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mazin Sabra against Clearpoint Neuro stock is an integral part of due diligence when investing in Clearpoint Neuro. Mazin Sabra insider activity provides valuable insight into whether Clearpoint Neuro is net buyers or sellers over its current business cycle. Note, Clearpoint Neuro insiders must abide by specific rules, including filing SEC forms every time they buy or sell Clearpoint Neuro'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mazin Sabra over a week ago Acquisition by Mazin Sabra of 6913 shares of Clearpoint Neuro subject to Rule 16b-3 | ||
Mazin Sabra over two weeks ago Acquisition by Mazin Sabra of 65252 shares of Clearpoint Neuro subject to Rule 16b-3 | ||
Mazin Sabra over three months ago Disposition of 7465 shares by Mazin Sabra of Clearpoint Neuro at 11. subject to Rule 16b-3 | ||
Mazin Sabra over three months ago Disposition of 6913 shares by Mazin Sabra of Clearpoint Neuro subject to Rule 16b-3 |
Clearpoint Neuro Management Efficiency
The company has return on total asset (ROA) of (0.2804) % which means that it has lost $0.2804 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6836) %, meaning that it created substantial loss on money invested by shareholders. Clearpoint Neuro's management efficiency ratios could be used to measure how well Clearpoint Neuro manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.5 in 2025. Return On Capital Employed is likely to drop to -0.77 in 2025. At this time, Clearpoint Neuro's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 1.6 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 4.7 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Geoffrey Rose | Pulmonx Corp | 51 | |
| Marco Dolci | LivaNova PLC | 62 | |
| Reay Brown | Sight Sciences | N/A | |
| James Mazzola | Outset Medical | N/A | |
| Georgia Melenikiotou | Inspire Medical Systems | 61 | |
| Paul Badawi | Sight Sciences | 50 | |
| Rebecca Kuhn | Neuropace | 64 | |
| Jeremy Hayden | Sight Sciences | 54 | |
| Skott Greenhalgh | Tela Bio | 56 | |
| Nicole Shannon | Outset Medical | N/A | |
| Chi Nguyen | Neuropace | 47 | |
| Kathy McGee | Avita Medical | 58 | |
| Andre Marquette | Neuropace | N/A | |
| JeanOlivier Racine | Outset Medical | 42 | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| Derrick Sung | Pulmonx Corp | 51 | |
| Lindsey Little | LivaNova PLC | N/A | |
| Antony Koblish | Tela Bio | 59 | |
| Erin Liberto | Avita Medical | 49 | |
| Michael Favet | Neuropace | 54 | |
| John McKune | Pulmonx Corp | 49 | |
Management Performance
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.28 |
Clearpoint Neuro Leadership Team
Elected by the shareholders, the Clearpoint Neuro's board of directors comprises two types of representatives: Clearpoint Neuro inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clearpoint. The board's role is to monitor Clearpoint Neuro's management team and ensure that shareholders' interests are well served. Clearpoint Neuro's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clearpoint Neuro's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Burnett, CEO President | ||
| Mazin Sabra, Chief Officer | ||
| Danilo DAlessandro, Chief Officer | ||
| Ellisa JD, General Secretary | ||
| Ellisa Cholapranee, General Secretary | ||
| Jeremy Stigall, Executive Delivery | ||
| Jacqueline Keller, Vice Marketing |
Clearpoint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clearpoint Neuro a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 467.89 M | ||||
| Shares Outstanding | 27.58 M | ||||
| Shares Owned By Insiders | 7.71 % | ||||
| Shares Owned By Institutions | 30.43 % | ||||
| Number Of Shares Shorted | 838.64 K | ||||
| Price To Earning | (3.36) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.